ATRX and neoplasm: Therefore, future studies must consider important tumor-specific genetic, epigenetic, and transcriptomic alterations before and after therapy, such as MEN1/DAXX/ATRX mutations, ARX expression, and their corresponding phenotypic manifestations (i.e., ALT), as defining characteristics that may impact tumor recurrence and the survival of patients with PNETs.